ABCF3

Summary

ABCF3 (ATP binding cassette subfamily F member 3, HGNC:72) is a protein-coding gene on chromosome 3q27.1, encoding ATP-binding cassette sub-family F member 3 (Q9NUQ8). Displays an antiviral effect against flaviviruses such as west Nile virus (WNV) in the presence of OAS1B.

This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. ATP-binding cassette proteins transport various molecules across extra- and intracellular membranes. The protein encoded by this gene displays antiviral effect against flaviviruses. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 55324 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 139 total
• MANE Select transcript: NM_018358

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:72
Approved symbol	ABCF3
Name	ATP binding cassette subfamily F member 3
Location	3q27.1
Locus type	gene with protein product
Status	Approved
Aliases	EST201864
Ensembl gene	ENSG00000161204
Ensembl biotype	protein_coding
OMIM	618967
Entrez	55324

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 15 retained_intron, 11 protein_coding, 1 nonsense_mediated_decay

ENST00000292808, ENST00000421340, ENST00000429586, ENST00000463685, ENST00000466416, ENST00000466742, ENST00000468892, ENST00000471226, ENST00000472608, ENST00000473311, ENST00000475728, ENST00000478288, ENST00000480539, ENST00000480562, ENST00000481116, ENST00000485921, ENST00000489719, ENST00000498136, ENST00000874864, ENST00000874865, ENST00000874866, ENST00000874867, ENST00000939999, ENST00000940000, ENST00000971452, ENST00000971453, ENST00000971454

RefSeq mRNA: 4 — MANE Select: NM_018358 NM_001351298, NM_001351299, NM_001351300, NM_018358

CCDS: CCDS3254, CCDS87173

Canonical transcript exons

ENST00000429586 — 21 exons

Exon	Start	End
ENSE00001302698	184193540	184194005
ENSE00001902109	184186199	184186280
ENSE00003469097	184192601	184192689
ENSE00003475451	184189255	184189277
ENSE00003484525	184189388	184189443
ENSE00003515334	184187397	184187443
ENSE00003524470	184188141	184188407
ENSE00003537133	184187861	184187983
ENSE00003541071	184192805	184192896
ENSE00003566093	184187664	184187761
ENSE00003569811	184186507	184186654
ENSE00003573866	184190999	184191043
ENSE00003578096	184189855	184189931
ENSE00003619121	184186796	184186875
ENSE00003627476	184193102	184193234
ENSE00003641600	184188929	184188988
ENSE00003642918	184191123	184191255
ENSE00003648406	184189088	184189144
ENSE00003669034	184193365	184193452
ENSE00003672091	184188761	184188841
ENSE00003673723	184189557	184189757

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 98.43.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.7464 / max 108.5483, expressed in 1818 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
40147	27.7464	1818

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland	UBERON:0001233	98.43	gold quality
right adrenal gland cortex	UBERON:0035827	98.43	gold quality
left adrenal gland cortex	UBERON:0035825	98.08	gold quality
left adrenal gland	UBERON:0001234	98.04	gold quality
adrenal cortex	UBERON:0001235	97.46	gold quality
adrenal gland	UBERON:0002369	97.23	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.94	gold quality
cerebellar hemisphere	UBERON:0002245	96.62	gold quality
cerebellar cortex	UBERON:0002129	96.55	gold quality
apex of heart	UBERON:0002098	96.19	gold quality
adenohypophysis	UBERON:0002196	96.09	gold quality
right lobe of thyroid gland	UBERON:0001119	95.57	gold quality
body of pancreas	UBERON:0001150	95.52	gold quality
right ovary	UBERON:0002118	95.44	gold quality
left ovary	UBERON:0002119	95.42	gold quality
metanephros cortex	UBERON:0010533	95.34	gold quality
right lobe of liver	UBERON:0001114	95.27	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.07	gold quality
granulocyte	CL:0000094	94.96	gold quality
right frontal lobe	UBERON:0002810	94.94	gold quality
left lobe of thyroid gland	UBERON:0001120	94.89	gold quality
pituitary gland	UBERON:0000007	94.68	gold quality
cerebellum	UBERON:0002037	94.63	gold quality
stromal cell of endometrium	CL:0002255	94.53	gold quality
right uterine tube	UBERON:0001302	94.50	gold quality
body of stomach	UBERON:0001161	94.48	gold quality
mucosa of transverse colon	UBERON:0004991	94.43	gold quality
right atrium auricular region	UBERON:0006631	94.42	gold quality
minor salivary gland	UBERON:0001830	94.31	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.22	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.21
E-MTAB-4850	no	678.46

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

33 targeting ABCF3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-4524A-5P	99.57	71.73	1193
HSA-MIR-4524B-5P	99.57	71.68	1195
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-143-5P	98.98	68.87	946
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-615-5P	98.10	63.76	591
HSA-MIR-4665-5P	97.91	67.69	1536
HSA-MIR-503-5P	97.87	66.83	575
HSA-MIR-6793-3P	97.66	65.78	1084
HSA-MIR-10398-5P	97.12	64.94	1051

Literature-anchored findings (GeneRIF, showing 1)

• hABCF3 positively regulates cell proliferation, at least partially through the interaction with a tumor protein D52 protein family member: TPD52L2. (PMID:24052230)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	abcf3	ENSDARG00000089705
mus_musculus	Abcf3	ENSMUSG00000003234
rattus_norvegicus	Abcf3	ENSRNOG00000001710
drosophila_melanogaster	CG9330	FBGN0036888
caenorhabditis_elegans		WBGENE00018339

Paralogs (2): ABCF2 (ENSG00000033050), ABCF1 (ENSG00000204574)

Protein

Protein identifiers

ATP-binding cassette sub-family F member 3 — Q9NUQ8 (reviewed: Q9NUQ8)

All UniProt accessions (3): A0A0S2Z5L1, Q9NUQ8, F8WCU6

UniProt curated annotations — full annotation on UniProt →

Function. Displays an antiviral effect against flaviviruses such as west Nile virus (WNV) in the presence of OAS1B.

Similarity. Belongs to the ABC transporter superfamily. ABCF family. EF3 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NUQ8-1	1	yes
Q9NUQ8-2	2

RefSeq proteins (4): NP_001338227, NP_001338228, NP_001338229, NP_060828* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003439	ABC_transporter-like_ATP-bd	Domain
IPR003593	AAA+_ATPase	Domain
IPR017871	ABC_transporter-like_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR032781	ABC_tran_Xtn	Domain
IPR050611	ABCF	Family
IPR058770	PWI_ABCF3	Domain

Pfam: PF00005, PF12848, PF26051

UniProt features (21 total): modified residue 6, sequence conflict 3, sequence variant 2, domain 2, compositionally biased region 2, binding site 2, initiator methionine 1, chain 1, splice variant 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NUQ8-F1	81.77	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 210–217; 525–532

Post-translational modifications (6): 83, 155, 157, 161, 283, 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 96 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, AP1_01, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, TGACCTY_ERR1_Q2, AP1_Q4_01, TGCTGAY_UNKNOWN, BACH2_01, E4F1_Q6, TGANTCA_AP1_C, GOBP_DEFENSE_RESPONSE_TO_VIRUS, NFE2_01, GOBP_RESPONSE_TO_VIRUS, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, WANG_TUMOR_INVASIVENESS_UP

GO Biological Process (1): defense response to virus (GO:0051607)

GO Molecular Function (5): ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), cadherin binding (GO:0045296), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
defense response	1
response to virus	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
ATP-dependent activity	1
cell adhesion molecule binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

3486 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ABCF3	GCN1	Q92616	782
ABCF3	ABCD4	O14678	666
ABCF3	ABCB9	Q9NP78	607
ABCF3	ABCC5	O15440	597
ABCF3	ABCG4	Q9H172	586
ABCF3	ABCB6	Q9NP58	575
ABCF3	ABCC6	P78420	551
ABCF3	ABCA5	Q8WWZ7	551
ABCF3	ABCA10	Q8WWZ4	528
ABCF3	TAP1	Q03518	526
ABCF3	ABCE1	P61221	518
ABCF3	ABCG8	Q9H221	475
ABCF3	CFAP99	D6REC4	475
ABCF3	ABCG5	Q9H222	472
ABCF3	ABCA6	Q8N139	462

IntAct

117 interactions, top by confidence:

A	B	Type	Score
TRIM27	ABCF3	psi-mi:“MI:0915”(physical association)	0.780
ABCF3	TRIM27	psi-mi:“MI:0915”(physical association)	0.780
RFXANK	RFXAP	psi-mi:“MI:0914”(association)	0.780
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
ABCF3	FCHSD2	psi-mi:“MI:0915”(physical association)	0.670
FCHSD2	ABCF3	psi-mi:“MI:0915”(physical association)	0.670
ABCF3		psi-mi:“MI:0915”(physical association)	0.560
	ABCF3	psi-mi:“MI:0915”(physical association)	0.560
HSPB8	VWA8	psi-mi:“MI:0914”(association)	0.530
ZNRD2	MYO9A	psi-mi:“MI:0914”(association)	0.530
ASB6	POLR2D	psi-mi:“MI:0914”(association)	0.530
HUS1B	RAD1	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
SKA2	VSIG8	psi-mi:“MI:0914”(association)	0.530
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
PIP5KL1	ABCF3	psi-mi:“MI:0915”(physical association)	0.400
ABCF3	CCDC33	psi-mi:“MI:0915”(physical association)	0.370
Skp1	XPO1	psi-mi:“MI:0914”(association)	0.350
PPP2R1A	INTS2	psi-mi:“MI:0914”(association)	0.350
HSPA5	NCOR2	psi-mi:“MI:0914”(association)	0.350
FOXL1	DDX39A	psi-mi:“MI:0914”(association)	0.350

BioGRID (137): ABCF3 (Two-hybrid), ABCF3 (Two-hybrid), CCDC33 (Two-hybrid), ABCF3 (Affinity Capture-RNA), ABCF3 (Affinity Capture-RNA), ABCF3 (Affinity Capture-MS), ABCF2 (Co-fractionation), ABCF3 (Co-fractionation), ABCF3 (Co-fractionation), ABCF3 (Co-fractionation), NLRP9 (Co-fractionation), ABCF3 (Affinity Capture-MS), TRIM27 (Two-hybrid), ABCF3 (Affinity Capture-MS), ABCF3 (Affinity Capture-MS)

ESM2 similar proteins: A0A0D1CLQ4, A0A139AVY4, A9X4T1, B9FK36, C5E4D9, D0MYB4, G5EES6, J9VQZ9, O14134, O42943, O59672, O93796, O94489, P06625, P08240, P16521, P16638, P25997, P29551, P40024, P43535, P53396, P53585, P53978, Q08972, Q2KJA2, Q2TCH3, Q32PF2, Q3MHE8, Q4HY71, Q5KIM6, Q5R9Z5, Q66H39, Q6MG08, Q75EV6, Q767L0, Q7YR37, Q8H0V6, Q8K268, Q8NE71

Diamond homologs: A0A0H2VBH0, A0A0H2VFI8, A0KPH6, A1AC19, A1B9H9, A1JRI2, A1U776, O05519, O06476, O31716, O34512, O34631, O42943, O59672, P0A9U3, P0A9U4, P0A9U5, P0A9W3, P0A9W4, P0A9W5, P0A9X1, P0A9X2, P0A9X3, P12622, P25256, P40024, P43535, P43672, P44808, P45127, P57403, P63389, P63390, P9WQK2, P9WQK3, Q0I4A9, Q0T3U8, Q0TGX4, Q0VTB6, Q1C1S0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 151 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA Splicing	9	11.2×	6e-05
PKR-mediated signaling	6	9.6×	5e-03
Processing of Capped Intron-Containing Pre-mRNA	9	8.4×	4e-04
mRNA Splicing - Major Pathway	10	6.2×	9e-04
Metabolism of RNA	11	5.2×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

139 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	93
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2533 predictions. Top by Δscore:

Variant	Effect	Δscore
3:184186276:GACCG:G	donor_gain	1.0000
3:184186279:CGGT:C	donor_loss	1.0000
3:184186280:GGTAA:G	donor_loss	1.0000
3:184186281:G:GG	donor_gain	1.0000
3:184186281:G:T	donor_loss	1.0000
3:184186282:T:A	donor_loss	1.0000
3:184186473:C:CA	acceptor_gain	1.0000
3:184186491:ACCAC:A	acceptor_gain	1.0000
3:184186495:C:CA	acceptor_gain	1.0000
3:184186506:GGC:G	acceptor_gain	1.0000
3:184186651:GTCT:G	donor_gain	1.0000
3:184186655:G:GG	donor_gain	1.0000
3:184186666:G:GT	donor_gain	1.0000
3:184186792:ATAG:A	acceptor_gain	1.0000
3:184187452:G:GT	donor_gain	1.0000
3:184187455:G:GT	donor_gain	1.0000
3:184187463:G:GT	donor_gain	1.0000
3:184187464:G:T	donor_gain	1.0000
3:184187607:T:TA	acceptor_gain	1.0000
3:184187608:G:A	acceptor_gain	1.0000
3:184187620:T:A	acceptor_gain	1.0000
3:184187762:G:GG	donor_gain	1.0000
3:184188140:GA:G	acceptor_gain	1.0000
3:184188406:AGGTG:A	donor_loss	1.0000
3:184188407:GGTGA:G	donor_loss	1.0000
3:184188408:GTG:G	donor_loss	1.0000
3:184188409:T:A	donor_loss	1.0000
3:184188755:CTCCA:C	acceptor_loss	1.0000
3:184188756:TCCA:T	acceptor_loss	1.0000
3:184188759:A:AG	acceptor_gain	1.0000

AlphaMissense

4612 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:184188215:G:A	G215E	1.000
3:184188221:C:T	T217I	1.000
3:184189391:C:A	P354H	1.000
3:184189870:T:C	F444L	1.000
3:184189872:T:A	F444L	1.000
3:184189872:T:G	F444L	1.000
3:184188190:G:T	G207W	0.999
3:184188191:G:A	G207E	0.999
3:184188200:G:A	G210E	0.999
3:184188207:T:A	N212K	0.999
3:184188207:T:G	N212K	0.999
3:184188209:G:A	G213E	0.999
3:184188214:G:A	G215R	0.999
3:184188214:G:C	G215R	0.999
3:184188215:G:T	G215V	0.999
3:184188217:A:C	K216Q	0.999
3:184188219:G:C	K216N	0.999
3:184188219:G:T	K216N	0.999
3:184188943:T:A	L311H	0.999
3:184188943:T:C	L311P	0.999
3:184188957:T:C	F316L	0.999
3:184188958:T:C	F316S	0.999
3:184188959:T:A	F316L	0.999
3:184188959:T:G	F316L	0.999
3:184189102:G:A	G331D	0.999
3:184189114:G:T	R335M	0.999
3:184189123:T:C	L338P	0.999
3:184189126:C:A	A339D	0.999
3:184189263:T:C	L348P	0.999
3:184189266:T:A	L349Q	0.999

dbSNP variants (sampled 300 via entrez): RS1000284977 (3:184184665 C>T), RS1000401479 (3:184184938 A>C,G), RS1000628076 (3:184190250 T>C,G), RS1000855803 (3:184192210 A>G), RS1000908285 (3:184189219 G>A,T), RS1001245947 (3:184191459 T>C), RS1001290429 (3:184185827 G>A), RS1001573599 (3:184192589 A>G,T), RS1001795487 (3:184187161 G>A,C,T), RS1003150817 (3:184188659 T>C), RS1003415520 (3:184188688 C>A,T), RS1003468276 (3:184188431 A>G,T), RS1003647810 (3:184194001 G>A,C), RS1004175091 (3:184192524 A>C,G), RS1004426132 (3:184186686 C>T)

Disease associations

OMIM: gene MIM:618967 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001469_1	Major depressive disorder	5.000000e-06
GCST010699_102	Brain morphology (min-P)	2.000000e-11
GCST010701_37	Cortical surface area (MOSTest)	2.000000e-24
GCST010702_18	Subcortical volume (MOSTest)	5.000000e-08
GCST010703_130	Brain morphology (MOSTest)	3.000000e-08
GCST90000025_678	Appendicular lean mass	1.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement
EFO:0004980	appendicular lean mass

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects splicing, decreases expression	2
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
cupric chloride	increases expression	1
azoxystrobin	decreases expression	1
bisphenol B	increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	affects expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Diazinon	increases methylation	1
Doxorubicin	increases expression	1
Environmental Pollutants	affects expression	1
Ivermectin	decreases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Ribonucleotides	affects binding	1
Rotenone	decreases expression	1
Selenium	increases expression	1
Tetrachlorodibenzodioxin	decreases expression, affects cotreatment	1
Triiodothyronine	affects cotreatment, decreases expression	1
Zidovudine	increases expression	1
Aflatoxin B1	increases methylation	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1IM	Abcam HeLa ABCF3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer